Skip to main content
SpringerLink
Log in

Liver Disease in Pediatric Inflammatory Bowel Disease

  • Chapter
  • First Online:
Pediatric Inflammatory Bowel Disease

  • 1125 Accesses

Abstract

Hepatobiliary diseases are among the most common extraintestinal manifestations of inflammatory bowel disease (IBD). These include immune-mediated liver diseases, namely, primary sclerosing cholangitis, autoimmune hepatitis, and an overlap condition between the two, termed autoimmune sclerosing cholangitis. More recently, an additional entity that likely shares an immunological basis, known as IgG4-associated cholangitis (IAC), has been defined and observed to also occur in association with IBD. A number of hepatobiliary manifestations can result from the adverse effects of medications used to treat pediatric IBD, such as methotrexate, thiopurines, and antitumor necrosis factor-α antibodies. Another category of hepatobiliary involvement is that which reflects the pathophysiology of IBD, such as cholelithiasis. Abnormal liver biochemistry is common in children with IBD. While often transient and of little consequence, such abnormalities may occasionally herald serious underlying liver disease or medication toxicity. The challenge lies in determining which patients warrant further investigation and intervention versus simple observation. This chapter strives to facilitate this task by providing an overview of and suggesting clinical approaches to various hepatobiliary conditions associated with pediatric IBD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1598–619. doi:10.1002/ibd.21219.

    Article  PubMed  Google Scholar 

  2. Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Mate J. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007;13:1106–14. doi:10.1002/ibd.20160.

    Article  PubMed  Google Scholar 

  3. Mendes FD, Levy C, Enders FB, Loftus Jr EV, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007;102:344–50. doi:10.1111/j.1572-0241.2006.00947.x.

    Article  PubMed  Google Scholar 

  4. Yamamoto-Furusho JK, Sanchez-Osorio M, Uribe M. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann Hepatol. 2010;9:397–401.

    PubMed  Google Scholar 

  5. Nemeth A, Ejderhamn J, Glaumann H, Strandvik B. Liver damage in juvenile inflammatory bowel disease. Liver. 1990;10:239–48.

    Article  CAS  PubMed  Google Scholar 

  6. Pusateri AJ, Kim SC, Dotson JL, Balint JP, Potter CJ, Boyle BM, Crandall WV. Incidence, pattern, and etiology of elevated liver enzymes in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2015;60:592–7. doi:10.1097/MPG.0000000000000672.

    Article  CAS  PubMed  Google Scholar 

  7. Valentino PL, Feldman BM, Walters TD, Griffiths AM, Ling SC, Pullenayegum EM, Kamath BM. Abnormal liver biochemistry is common in pediatric inflammatory bowel disease: prevalence and associations. Inflamm Bowel Dis. 2015; doi:10.1097/MIB.0000000000000558.

    PubMed  Google Scholar 

  8. Hyams J, Markowitz J, Treem W, Davis P, Grancher K, Daum F. Characterization of hepatic abnormalities in children with inflammatory bowel disease. Inflamm Bowel Dis. 1995;1:27–33.

    CAS  PubMed  Google Scholar 

  9. Goyal A, Hyams JS, Lerer T, et al. Liver enzyme elevations within 3 months of diagnosis of inflammatory bowel disease and likelihood of liver disease. J Pediatr Gastroenterol Nutr. 2014;59:321–3. doi:10.1097/mpg.0000000000000409.

    Article  CAS  PubMed  Google Scholar 

  10. Riegler G, D’Inca R, Sturniolo GC, et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Caprilli & Gruppo Italiano Studio Colon-Retto. Scand J Gastroenterol. 1998;33:93–8.

    Article  CAS  PubMed  Google Scholar 

  11. Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol. 2008;48:939–44. doi:10.1016/j.jhep.2008.02.017.

    Article  PubMed  Google Scholar 

  12. Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology. 2013;58:1392–400. doi:10.1002/hep.26454.

    Article  PubMed  Google Scholar 

  13. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042–9. doi:10.1111/j.1572-0241.2007.01103.x.

    Article  PubMed  Google Scholar 

  14. Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology. 2003;38:210–7. doi:10.1053/jhep.2003.50289.

    Article  PubMed  Google Scholar 

  15. Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol. 2009;7:239–45. doi:10.1016/j.cgh.2008.10.019.

    Article  PubMed  Google Scholar 

  16. Wilschanski M, Chait P, Wade JA, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology. 1995;22:1415–22.

    CAS  PubMed  Google Scholar 

  17. Warren KW, Athanassiades S, Monge JI. Primary sclerosing cholangitis. A study of forty-two cases. Am J Surg. 1966;111:23–38.

    Article  CAS  PubMed  Google Scholar 

  18. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–8. doi:10.1016/j.jhep.2011.10.025.

    Article  PubMed  Google Scholar 

  19. Schrumpf E, Boberg KM. Epidemiology of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001;15:553–62. doi:10.1053/bega.2001.0204.

    Article  CAS  PubMed  Google Scholar 

  20. Batres LA, Russo P, Mathews M, Piccoli DA, Chuang E, Ruchelli E. Primary sclerosing cholangitis in children: a histologic follow-up study. Pediatr Dev Pathol. 2005;8:568–76. doi:10.1007/s10024-005-0020-0.

    Article  PubMed  Google Scholar 

  21. Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr. 2010;51:140–5. doi:10.1097/MPG.0b013e3181ca4db4.

    Article  PubMed  Google Scholar 

  22. Jose FA, Garnett EA, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:63–8. doi:10.1002/ibd.20604.

    Article  PubMed  Google Scholar 

  23. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–78. doi:10.1002/hep.23294.

    Article  CAS  PubMed  Google Scholar 

  24. Mells GF, Kaser A, Karlsen TH. Novel insights into autoimmune liver diseases provided by genome-wide association studies. J Autoimmun. 2013;46:41–54. doi:10.1016/j.jaut.2013.07.004.

    Article  CAS  PubMed  Google Scholar 

  25. Williamson KD, Chapman RW. Primary sclerosing cholangitis: a clinical update. Br Med Bull. 2015;114:53–64. doi:10.1093/bmb/ldv019.

    Article  PubMed  Google Scholar 

  26. Eksteen B, Grant AJ, Miles A, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med. 2004;200:1511–7. doi:10.1084/jem.20041035.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Tabibian JH, O’Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol. 2014;49:901–8. doi:10.3109/00365521.2014.913189.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Loftus Jr EV, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–6. doi:10.1136/gut.2004.046615.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Halliday JS, Djordjevic J, Lust M, Culver EL, Braden B, Travis SP, Chapman RW. A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn disease. J Crohn Colitis. 2012;6:174–81. doi: http://dx.doi.org/10.1016/j.crohns.2011.07.015.

    Article  CAS  Google Scholar 

  30. Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum. 1997;40:451–6.

    Article  CAS  PubMed  Google Scholar 

  31. Schaeffer DF, Win LL, Hafezi-Bakhtiari S, Cino M, Hirschfield GM, El-Zimaity H. The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis. Dig Dis Sci. 2013;58:2608–14. doi:10.1007/s10620-013-2697-7.

    Article  CAS  PubMed  Google Scholar 

  32. Faubion Jr WA, Loftus EV, Sandborn WJ, Freese DK, Perrault J. Pediatric “PSC-IBD”: a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr. 2001;33:296–300.

    Article  PubMed  Google Scholar 

  33. Ordonez F, Lacaille F, Canioni D, et al. Pediatric ulcerative colitis associated with autoimmune diseases: a distinct form of inflammatory bowel disease? Inflamm Bowel Dis. 2012;18:1809–17. doi:10.1002/ibd.22864.

    Article  PubMed  Google Scholar 

  34. Lascurain L, Jensen MK, Guthery SL, Holmen J, Deneau M. Inflammatory bowel disease phenotype in pediatric primary sclerosing cholangitis. Inflamm Bowel Dis. 2016;22:146–50. doi:10.1097/MIB.0000000000000586.

    Article  PubMed  Google Scholar 

  35. Marelli L, Xirouchakis E, Kalambokis G, Cholongitas E, Hamilton MI, Burroughs AK. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut. 2011;60:1224–8. doi:10.1136/gut.2010.235408.

    Article  PubMed  Google Scholar 

  36. Cangemi JR, Wiesner RH, Beaver SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology. 1989;96:790–4.

    Article  CAS  PubMed  Google Scholar 

  37. Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14:138–43. doi:10.1002/lt.21260.

    Article  PubMed  Google Scholar 

  38. Bjornsson E, Chari S, Silveira M, Gossard A, Takahashi N, Smyrk T, Lindor K. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther. 2011;18:198–205. doi:10.1097/MJT.0b013e3181c9dac6.

    Article  PubMed  Google Scholar 

  39. Lindor KD, Kowdley KV, Harrison ME. ACG Clinical Guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646–59. quiz 660 doi:10.1038/ajg.2015.112.

    Article  CAS  PubMed  Google Scholar 

  40. MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology. 1983;149:39–44. doi:10.1148/radiology.149.1.6412283.

    Article  CAS  PubMed  Google Scholar 

  41. Deneau M, Adler DG, Schwartz JJ, et al. Cholangiocarcinoma in a 17-year-old boy with primary sclerosing cholangitis and inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52:617–20. doi:10.1097/MPG.0b013e3181f9a5d2.

    Article  PubMed  Google Scholar 

  42. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48–54.

    Article  PubMed  Google Scholar 

  43. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut. 2002;51:562–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Bjornsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134:975–80. doi:10.1053/j.gastro.2008.01.042.

    Article  PubMed  Google Scholar 

  45. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol. 2013;7:103–14. doi:10.1586/egh.12.80.

    Article  CAS  PubMed  Google Scholar 

  46. Gilger MA, Gann ME, Opekun AR, Gleason Jr WA. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children. J Pediatr Gastroenterol Nutr. 2000;31:136–41.

    Article  CAS  PubMed  Google Scholar 

  47. Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34:901–10. doi:10.1111/j.1365-2036.2011.04822.x.

    Article  CAS  PubMed  Google Scholar 

  48. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808–14. doi:10.1002/hep.23082.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998;27:580–3.

    Article  CAS  PubMed  Google Scholar 

  50. Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr. 2008;47:61–7. doi:10.1097/MPG.0b013e31816fee95.

    Article  CAS  PubMed  Google Scholar 

  51. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis – a pilot study. Aliment Pharmacol Ther. 2013;37:604–12. doi:10.1111/apt.12232.

    Article  CAS  PubMed  Google Scholar 

  52. Abarbanel DN, Seki SM, Davies Y, et al. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol. 2013;33:397–406. doi:10.1007/s10875-012-9801-1.

    Article  CAS  PubMed  Google Scholar 

  53. Farkkila M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, Karkkainen P. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40:1379–86. doi:10.1002/hep.20457.

    Article  PubMed  CAS  Google Scholar 

  54. Silveira MG, Torok NJ, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor KD. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol. 2009;104:83–8. doi:10.1038/ajg.2008.14.

    Article  CAS  PubMed  Google Scholar 

  55. Tabibian JH, Gossard A, El-Youssef M, et al. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther. 2014; doi:10.1097/mjt.0000000000000102.

    Google Scholar 

  56. Johnson GK, Saeian K, Geenen JE. Primary sclerosing cholangitis treated by endoscopic biliary dilation: review and long-term follow-up evaluation. Curr Gastroenterol Rep. 2006;8:147–55.

    Article  PubMed  Google Scholar 

  57. Venkat VL, Ranganathan S, Sindhi R. The challenges of liver transplantation in children with primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol. 2015;9:289–94. doi:10.1586/17474124.2015.1002085.

    Article  CAS  PubMed  Google Scholar 

  58. Squires RH, Ng V, Romero R, Ekong U, Hardikar W, Emre S, Mazariegos GV. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2014;59:112–31. doi:10.1097/mpg.0000000000000431.

    Article  PubMed  Google Scholar 

  59. Miloh T, Anand R, Yin W, Vos M, Kerkar N, Alonso E, Studies of Pediatric Liver Transplantation Research Group. Pediatric liver transplantation for primary sclerosing cholangitis. Liver Transpl. 2011;17:925–33. doi:10.1002/lt.22320.

    Article  PubMed  Google Scholar 

  60. Venkat VL, Ranganathan S, Mazariegos GV, Sun Q, Sindhi R. Recurrence of primary sclerosing cholangitis in pediatric liver transplant recipients. Liver Transpl. 2014;20:679–86. doi:10.1002/lt.23868.

    Article  PubMed  Google Scholar 

  61. Jimenez-Rivera C, Ling SC, Ahmed N, et al. Incidence and characteristics of autoimmune hepatitis. Pediatrics. 2015; doi:10.1542/peds.2015-0578.

    PubMed  Google Scholar 

  62. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, Mieli-Vergani G. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33:544–53. doi:10.1053/jhep.2001.22131.

    Article  CAS  PubMed  Google Scholar 

  63. Mieli-Vergani G, Vergani D. Paediatric autoimmune liver disease. Arch Dis Child. 2013;98:1012–7. doi:10.1136/archdischild-2013-303848.

    Article  PubMed  Google Scholar 

  64. Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children: what is different from adult AIH? Semin Liver Dis. 2009;29:297–306. doi:10.1055/s-0029-1233529.

    Article  PubMed  Google Scholar 

  65. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology. 1997;25:541–7. doi:10.1002/hep.510250308.

    Article  CAS  PubMed  Google Scholar 

  66. Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis–update 2015. J Hepatol. 2015;62:S100–11. doi:10.1016/j.jhep.2015.03.005.

    Article  PubMed  Google Scholar 

  67. Mieli-Vergani G, Vergani D. Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol. 2011;8:320–9. doi:10.1038/nrgastro.2011.69.

    Article  CAS  PubMed  Google Scholar 

  68. Radhakrishnan KR, Alkhouri N, Worley S, et al. Autoimmune hepatitis in children–impact of cirrhosis at presentation on natural history and long-term outcome. Dig Liver Dis. 2010;42:724–8. doi:10.1016/j.dld.2010.01.002.

    Article  PubMed  Google Scholar 

  69. Floreani A, Liberal R, Vergani D, Mieli-Vergani G. Autoimmune hepatitis: contrasts and comparisons in children and adults – a comprehensive review. J Autoimmun. 2013;46:7–16. doi:10.1016/j.jaut.2013.08.004.

    Article  PubMed  Google Scholar 

  70. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198–206. doi:10.1053/j.gastro.2010.06.046.

    Article  CAS  PubMed  Google Scholar 

  71. Liberal R, Longhi MS, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis after liver transplantation. Clin Gastroenterol Hepatol. 2012;10:346–53. doi:10.1016/j.cgh.2011.10.028.

    Article  PubMed  Google Scholar 

  72. Liberal R, Zen Y, Mieli-Vergani G, Vergani D. Liver transplantation and autoimmune liver diseases. Liver Transpl. 2013;19:1065–77. doi:10.1002/lt.23704.

    PubMed  Google Scholar 

  73. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374–85. doi:10.1016/j.jhep.2010.09.002.

    Article  PubMed  Google Scholar 

  74. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–213. doi:10.1002/hep.23584.

    Article  CAS  PubMed  Google Scholar 

  75. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–67. doi:10.1016/j.jhep.2009.04.009.

    Article  Google Scholar 

  76. Beuers U, Hubers LM, Doorenspleet M, et al. IgG4-associated cholangitis – a mimic of PSC. Dig Dis. 2015;33(Suppl 2):176–80. doi:10.1159/000440830.

    Article  PubMed  Google Scholar 

  77. Dastis SN, Latinne D, Sempoux C, Geubel AP. Ulcerative colitis associated with IgG4 cholangitis: similar features in two HLA identical siblings. J Hepatol. 2009;51:601–5. doi:10.1016/j.jhep.2009.05.032.

    Article  CAS  PubMed  Google Scholar 

  78. Hirano K, Kawabe T, Yamamoto N, et al. Serum IgG4 concentrations in pancreatic and biliary diseases. Clin Chim Acta. 2006;367:181–4. doi:10.1016/j.cca.2005.11.031.

    Article  CAS  PubMed  Google Scholar 

  79. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070–5. doi:10.1111/j.1572-0241.2006.00772.x.

    Article  CAS  PubMed  Google Scholar 

  80. Zhang L, Lewis JT, Abraham SC, et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol. 2010;34:88–94. doi:10.1097/PAS.0b013e3181c6c09a.

    Article  PubMed  Google Scholar 

  81. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–15. doi:10.1053/j.gastro.2007.12.009.

    Article  PubMed  Google Scholar 

  82. Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19:536–42. doi:10.1007/s00534-012-0521-y.

    Article  PubMed  Google Scholar 

  83. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum. 2015;45:156–62. doi:10.1016/j.semarthrit.2015.05.003.

    Article  CAS  PubMed  Google Scholar 

  84. Fournier MR, Klein J, Minuk GY, Bernstein CN. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol. 2010;105:1620–6. doi:10.1038/ajg.2010.21.

    Article  CAS  PubMed  Google Scholar 

  85. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95:3150–6. doi:10.1111/j.1572-0241.2000.03287.x.

    Article  CAS  PubMed  Google Scholar 

  86. Sunseri W, Hyams JS, Lerer T, et al. Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn disease. Inflamm Bowel Dis. 2014;20:1341–5. doi:10.1097/mib.0000000000000102.

    Article  PubMed  Google Scholar 

  87. Turner D, Doveh E, Cohen A, et al. Efficacy of oral methotrexate in paediatric Crohn disease: a multicentre propensity score study. Gut. 2015;64(12):1898–904. doi:10.1136/gutjnl-2014-307964. Epub 2014 Nov 21.

  88. Valentino PL, Church PC, Shah PS, Beyene J, Griffiths AM, Feldman BM, Kamath BM. Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:47–59. doi:10.1097/01.MIB.0000436953.88522.3e.

    Article  PubMed  Google Scholar 

  89. Khan N, Abbas AM, Whang N, Balart LA, Bazzano LA, Kelly TN. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis. 2012;18:359–67. doi:10.1002/ibd.21820.

    Article  PubMed  Google Scholar 

  90. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60:824–37. doi:10.1016/j.jaad.2008.11.906.

    Article  PubMed  Google Scholar 

  91. Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:659–66. doi:10.1586/eci.10.46.

    Article  CAS  PubMed  Google Scholar 

  92. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2007;102:1518–27. doi:10.1111/j.1572-0241.2007.01187.x.

    Article  CAS  PubMed  Google Scholar 

  93. Lee MN, Kang B, Choi SY, et al. Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine. Inflamm Bowel Dis. 2015;21:1054–62. doi:10.1097/MIB.0000000000000347.

    Article  CAS  PubMed  Google Scholar 

  94. Riello L, Talbotec C, Garnier-Lengline H, et al. Tolerance and efficacy of azathioprine in pediatric Crohn disease. Inflamm Bowel Dis. 2011;17:2138–43. doi:10.1002/ibd.21612.

    Article  PubMed  Google Scholar 

  95. Haboubi NY, Ali HH, Whitwell HL, Ackrill P. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol. 1988;83:256–61.

    CAS  PubMed  Google Scholar 

  96. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003;125:298–303. doi:10.1016/s0016-5085(03)00938-7.

    Article  CAS  PubMed  Google Scholar 

  97. Calabrese E, Hanauer SB. Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease. J Crohns Colitis. 2011;5:48–53. doi:10.1016/j.crohns.2010.08.007.

    Article  PubMed  Google Scholar 

  98. Seiderer J, Zech CJ, Reinisch W, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol. 2005;43:303–9. doi:10.1016/j.jhep.2005.02.051.

    Article  CAS  PubMed  Google Scholar 

  99. Musumba CO. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy. Aliment Pharmacol Ther. 2013;38:1025–37. doi:10.1111/apt.12490.

    Article  CAS  PubMed  Google Scholar 

  100. Russmann S, Zimmermann A, Krähenbühl S, Kern B, Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol. 2001;13:287–90.

    Article  CAS  PubMed  Google Scholar 

  101. Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis. 2010;28:508–18. doi:10.1159/000320410.

    Article  PubMed  Google Scholar 

  102. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705–13.

    Article  CAS  PubMed  Google Scholar 

  103. Konidari A, Anagnostopoulos A, Bonnett LJ, Pirmohamed M, El-Matary W. Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. Br J Clin Pharmacol. 2014;78:467–76. doi:10.1111/bcp.12365.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Connor V. Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int. 2011;31:327–37. doi:10.1007/s00296-009-1292-x.

    Article  CAS  PubMed  Google Scholar 

  105. Vaz JL, Fernandes V, Nogueira F, Arnobio A, Levy RA. Infliximab-induced autoantibodies: a multicenter study. Clin Rheumatol. 2015; doi:10.1007/s10067-015-3140-6.

    Google Scholar 

  106. Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013;58:529–34. doi:10.1016/j.jhep.2012.11.010.

    Article  CAS  PubMed  Google Scholar 

  107. Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11:558–564.e553. doi:10.1016/j.cgh.2012.12.025.

    Article  CAS  PubMed  Google Scholar 

  108. Shelton E, Chaudrey K, Sauk J, et al. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41:972–9. doi:10.1111/apt.13159.

    Article  CAS  PubMed  Google Scholar 

  109. Bjornsson ES, Gunnarsson BI, Grondal G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015;13:602–8. doi:10.1016/j.cgh.2014.07.062.

    Article  CAS  PubMed  Google Scholar 

  110. Loras C, Gisbert JP, Minguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59:1340–6. doi:10.1136/gut.2010.208413.

    Article  CAS  PubMed  Google Scholar 

  111. Lin MV, Blonski W, Buchner AM, Reddy KR, Lichtenstein GR. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. Dig Dis Sci. 2013;58:1149–56.

    Article  CAS  PubMed  Google Scholar 

  112. Park SH, Yang SK, Park SK, et al. Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:69–74. doi:10.1097/01.MIB.0000437736.91712.a1.

    Article  PubMed  Google Scholar 

  113. Boyer DL, Li BU, Fyda JN, Friedman RA. Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1989;8:528–32.

    Article  CAS  PubMed  Google Scholar 

  114. Bashir RM, Lewis JH. Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders. Gastroenterol Clin North Am. 1995;24:937–67.

    CAS  PubMed  Google Scholar 

  115. Jobanputra P, Amarasena R, Maggs F, et al. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord. 2008;9:48. doi:10.1186/1471-2474-9-48.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS. Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine. Am J Gastroenterol. 1986;81:205–8.

    CAS  PubMed  Google Scholar 

  117. Namias A, Bhalotra R, Donowitz M. Reversible sulfasalazine-induced granulomatous hepatitis. J Clin Gastroenterol. 1981;3:193–8.

    Article  CAS  PubMed  Google Scholar 

  118. Quallich LG, Greenson J, Haftel HM, Fontana RJ. Is it Crohn disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis. BMC Gastroenterol. 2001;1:8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51:536–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Braun M, Fraser GM, Kunin M, Salamon F, Tur-Kaspa R. Mesalamine-induced granulomatous hepatitis. Am J Gastroenterol. 1999;94:1973–4. doi:10.1111/j.1572-0241.1999.01245.x.

    Article  CAS  PubMed  Google Scholar 

  121. Stelzer T, Kohler S, Marques Maggio E, Heuss LT. An unusual cause of febrile hepatitis. BMJ Case Rep. 2015; 2015. doi: 10.1136/bcr-2014-205857.

  122. Stoschus B, Meybehm M, Spengler U, Scheurlen C, Sauerbruch T. Cholestasis associated with mesalazine therapy in a patient with Crohn disease. J Hepatol. 1997;26:425–8.

    Article  CAS  PubMed  Google Scholar 

  123. Hautekeete ML, Bourgeois N, Potvin P, et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology. 1992;103:1925–7.

    Article  CAS  PubMed  Google Scholar 

  124. Deltenre P, Berson A, Marcellin P, Degott C, Biour M, Pessayre D. Mesalazine (5-aminosalicylic acid) induced chronic hepatitis. Gut. 1999;44:886–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Sourianarayanane A, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:e279–85. doi:10.1016/j.crohns.2012.10.015.

    Article  PubMed  Google Scholar 

  126. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36–41 e31. doi:10.1016/j.cgh.2010.09.016.

    Article  CAS  PubMed  Google Scholar 

  127. Mason M, Siegel CA. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis. 2013;19:1306–21. doi:10.1097/MIB.0b013e3182807618.

    Article  PubMed  Google Scholar 

  128. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99–105. doi:10.1038/ajg.2012.334.

    Article  CAS  PubMed  Google Scholar 

  129. Gizard E, Ford AC, Bronowicki JP, Peyrin-Biroulet L. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:3–15. doi:10.1111/apt.12794.

    Article  CAS  PubMed  Google Scholar 

  130. Parente F, Pastore L, Bargiggia S, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology. 2007;45:1267–74. doi:10.1002/hep.21537.

    Article  PubMed  Google Scholar 

  131. Ehlin AG, Montgomery SM, Ekbom A, Pounder RE, Wakefield AJ. Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut. 2003;52:1117–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Margalit M, Elinav H, Ilan Y, Shalit M. Liver abscess in inflammatory bowel disease: report of two cases and review of the literature. J Gastroenterol Hepatol. 2004;19:1338–42. doi:10.1111/j.1440-1746.2004.03368.x.

    Article  PubMed  Google Scholar 

  133. Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60:937–43. doi:10.1136/gut.2010.228585.

    Article  PubMed  Google Scholar 

  134. Nylund CM, Goudie A, Garza JM, Crouch G, Denson LA. Venous thrombotic events in hospitalized children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;56:485–91. doi:10.1097/MPG.0b013e3182801e43.

    Article  PubMed  Google Scholar 

  135. Maconi G, Bolzacchini E, Dell’Era A, Russo U, Ardizzone S, de Franchis R. Portal vein thrombosis in inflammatory bowel diseases: a single-center case series. J Crohns Colitis. 2012;6:362–7. doi:10.1016/j.crohns.2011.10.003.

    Article  PubMed  Google Scholar 

  136. Kraut J, Berman JH, Gunasekaran TS, Allen R, McFadden J, Messersmith R, Pellettiere E. Hepatic vein thrombosis (Budd-Chiari syndrome) in an adolescent with ulcerative colitis. J Pediatr Gastroenterol Nutr. 1997;25:417–20.

    Article  CAS  PubMed  Google Scholar 

  137. Rahhal RM, Pashankar DS, Bishop WP. Ulcerative colitis complicated by ischemic colitis and Budd Chiari syndrome. J Pediatr Gastroenterol Nutr. 2005;40:94–7.

    Article  PubMed  Google Scholar 

  138. Socha P, Ryzko J, Janczyk W, Dzik E, Iwanczak B, Krzesiek E. Hepatic vein thrombosis as a complication of ulcerative colitis in a 12-year-old patient. Dig Dis Sci. 2007;52:1293–8. doi:10.1007/s10620-006-9503-8.

    Article  PubMed  Google Scholar 

  139. Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore). 1992;71:261–70.

    Article  CAS  Google Scholar 

  140. Serra I, Oller B, Manosa M, Naves JE, Zabana Y, Cabre E, Domenech E. Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome. J Crohns Colitis. 2010;4:269–74. doi:10.1016/j.crohns.2009.11.009.

    Article  PubMed  Google Scholar 

  141. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001;7:295–300.

    Article  CAS  PubMed  Google Scholar 

  142. Sattianayagam PT, Gillmore JD, Pinney JH, et al. Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci. 2013;58:1689–97. doi:10.1007/s10620-012-2549-x.

    Article  CAS  PubMed  Google Scholar 

  143. Tada F, Abe M, Nunoi H, et al. Ulcerative colitis complicated with primary biliary cirrhosis. Intern Med. 2011;50:2323–7. doi:10.2169/internalmedicine.50.5919.

    Article  PubMed  Google Scholar 

  144. Xiao WB, Liu YL. Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature. World J Gastroenterol. 2003;9:878–80.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Canada

    Amanda Ricciuto MDCM, FRCP(C) & Binita M. Kamath MBBChir, MRCP, MTR

  2. University of Toronto, Toronto, Canada

    Binita M. Kamath MBBChir, MRCP, MTR

Authors
  1. Amanda Ricciuto MDCM, FRCP(C)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Binita M. Kamath MBBChir, MRCP, MTR
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Binita M. Kamath MBBChir, MRCP, MTR .

Editor information

Editors and Affiliations

  1. Division of GI, Hepatology & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Petar Mamula

  2. Division of GI, Hepatology & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Andrew B. Grossman

  3. Division of GI, Hepatology & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Robert N. Baldassano

  4. Division of GI, Hepatology & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Judith R. Kelsen

  5. Division of Pediatric Gastroenterology & Nutrition, University of South Carolina School of Medicine - Greenville, Greenville, South Carolina, USA

    Jonathan E. Markowitz

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Ricciuto, A., Kamath, B.M. (2017). Liver Disease in Pediatric Inflammatory Bowel Disease. In: Mamula, P., Grossman, A., Baldassano, R., Kelsen, J., Markowitz, J. (eds) Pediatric Inflammatory Bowel Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-49215-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-49215-5_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-49213-1

  • Online ISBN: 978-3-319-49215-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation